[Form 4] Immunovant, Inc. Insider Trading Activity
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, reported selling 3,115 shares of common stock on May 20, 2026, at prices ranging from $30.41 to $32.95 per share. These sales were not discretionary and were executed solely to cover tax withholding obligations related to the vesting of restricted stock units (RSUs). Following these transactions, Melanie directly holds 244,973 shares of Immunovant common stock.
Immunovant (IMVT) director exercises options, sells 6,000 shares under 10b5-1 plan
Immunovant, Inc. director Atul Pande exercised stock options for 6,000 shares at $8.43 per share and simultaneously sold those 6,000 shares at $32.00 per share on May 20, 2026. This transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted in December 2025. Following these trades, Pande directly holds 116,731 common shares and indirectly holds 20,000 shares through a trust, with an additional 270,252 stock options remaining.
Immunovant director Atul Pande sells $192,000 in shares
Immunovant director Atul Pande sold $192,000 worth of company common stock on May 20, 2026, after exercising stock options. The transactions were conducted under a Rule 10b5-1 trading plan. Immunovant shares have seen a 147% surge over the last year, despite the company remaining unprofitable.
[144] Immunovant, Inc. SEC Filing
This article details an SEC Form 144 filing by Immunovant, Inc. (IMVT) on May 20, 2026, indicating a proposed sale of 6,000 shares of common stock with an aggregate market value of $157,740. The securities were acquired through the exercise of stock options on the same day. The filing notes that the sale is to be handled by Morgan Stanley Smith Barney LLC on NASDAQ.
Immunovant, Inc. Stock 12‑Month Price Target Raised to $43.08, Implies 64% Upside
Immunovant, Inc.'s average 12-month stock price target has been increased from $40.29 to $43.08 by 12 analysts, implying a potential upside of 64% from its May 19 closing price. The consensus rating for the company remains a "Buy" among 13 analysts, with 9 recommending to buy, 4 to hold, and none to sell. Investors can find more detailed price target data and track analyst recommendations on the Forecasts tab and in the dedicated News Flow section.
Immunovant rises on IMVT-1402 data in difficult-to-treat RA
Immunovant (NASDAQ:IMVT) shares increased by 35% following the release of initial, promising Phase IIb data for its next-generation FcRn inhibitor, IMVT-1402. The study focused on patients with difficult-to-treat rheumatoid arthritis, including those unresponsive to TNF and JAK inhibitors. This positive data suggests a potential new treatment option for this challenging patient population.
Immunovant jumps 30.8% on upbeat IMVT-1402 rheumatoid arthritis update
Immunovant (IMVT) stock rose 30.8% following an encouraging clinical update on its IMVT-1402 program for difficult-to-treat rheumatoid arthritis, showing strong Week 16 response rates. The company also announced full enrollment for its cutaneous lupus erythematosus trial, with topline data expected in H2 2026, and highlighted a strong cash position of $902.1 million to fund operations through the potential commercial launch of IMVT-1402 for Graves' disease.
Immunovant (NASDAQ: IMVT) shifts to IMVT-1402 with broad late-stage autoimmune program
Immunovant (NASDAQ: IMVT) is re-focusing its entire pipeline on IMVT-1402, a next-generation antibody, due to its positive Phase 1 data showing deep IgG reductions without significant off-target effects. This shift follows the discontinuation of batoclimab after its Phase 3 trials for Thyroid Eye Disease failed to meet primary endpoints. Immunovant plans to advance IMVT-1402 through late-stage clinical trials across six autoimmune indications, including Graves’ disease, rheumatoid arthritis, myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, Sjögren’s disease, and cutaneous lupus erythematosus, leveraging prior clinical learnings and aiming for a best-in-class profile with subcutaneous self-administration.
Immunovant (IMVT) shifts to IMVT-1402 after batoclimab miss and $505.6M FY loss
Immunovant, Inc. (IMVT) announced its financial results for the fiscal year ended March 31, 2026, reporting a net loss of $505.6 million. The company is discontinuing its batoclimab program after two Phase 3 trials for thyroid eye disease failed to meet their primary endpoints, and is now fully focusing on its lead asset, IMVT-1402. Preliminary results for IMVT-1402 in difficult-to-treat rheumatoid arthritis showed encouraging response rates, and the company's cash position of $902.1 million is expected to fund operations through the potential commercial launch of IMVT-1402 in Graves’ disease.
S&P 500 Futures Rise in Premarket Trading; Immunovant, ImmunityBio Lead
S&P 500 futures showed an increase in premarket trading. Immunovant Inc. (IMVT) saw a significant rise of 22.7%, while ImmunityBio Inc. (IBRX) also performed well, gaining 9.3%. These movements occurred two hours before the official opening of U.S. stock markets.
Immunovant stock surges 8% despite earnings miss on drug trial data
Immunovant Inc. (NASDAQ:IMVT) reported a fourth-quarter loss that missed analyst estimates but saw its stock surge 8% due to promising clinical trial results for its lead drug candidate, IMVT-1402, in treating severe rheumatoid arthritis. The company also announced that other clinical development timelines for IMVT-1402 remain on track, with topline data for a cutaneous lupus erythematosus trial expected in H2 2026. Despite an increased net loss and R&D expenses, the company holds significant cash reserves to support the potential commercial launch of IMVT-1402.
Immunovant Inc stock (US45258Q1058): focus on upcoming earnings after trial setback
Immunovant Inc is preparing to report quarterly earnings, with investors closely watching for updates on its autoimmune drug pipeline, especially after a recent trial setback. The company, which is pre-revenue, will likely focus on its pipeline strategy, cash runway, and potential regulatory interactions rather than traditional earnings metrics. This high-risk biotech stock's valuation is heavily tied to successful clinical trials and future commercialization opportunities.
Immunovant earnings up next: investors eye path after trial miss By Investing.com
Immunovant (IMVT) is set to report its fourth-quarter fiscal 2026 results after a recent Phase 3 clinical trial failure impacted its lead drug candidate. Investors are now focused on the company's adjusted strategy, particularly the rapid advancement of its next-generation FcRn blocker, IMVT-1402, for various autoimmune conditions. Analysts are keenly watching management's articulation of their post-batoclimab strategy, detailed timelines for IMVT-1402 development, and the impact on cash burn and financial runway.
Immunovant Inc stock (US45258Q1058): earnings countdown and biotech hopes raise volatility
Immunovant Inc (IMVT) is nearing an earnings report where Wall Street anticipates a higher quarterly loss as the company continues to invest heavily in its autoimmune pipeline. The stock is currently trading near a 12-month high with high volatility, reflecting both investor hopes and the inherent risks of a clinical-stage biotechnology company dependent on capital markets. Key issues for investors include trial progress, cash runway, and potential future partnerships.
Immunovant stock (US45258Q1058): investors eye upcoming earnings date and autoimmune pipeline
Immunovant is a clinical-stage biotech company focused on developing FcRn-targeting antibodies for autoimmune diseases, with IMVT-1402 being its lead product candidate. Investors are keenly watching the company's upcoming earnings report and clinical milestones, as its value is tied to the success of its pipeline, scientific execution, and regulatory outcomes. The stock is a significant player on Nasdaq for US and international investors interested in the autoimmune therapeutics market.
How (IMVT) Movements Inform Risk Allocation Models
This article from Stock Traders Daily discusses Immunovant Inc. (NASDAQ: IMVT) and how its movements inform risk allocation models based on AI-generated signals. It highlights strong near-term sentiment with a long-term positive bias, noting a 46.7:1 risk-reward setup. The analysis provides specific institutional trading strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update on Wednesday, May 20, 2026, at 8:00 a.m. ET. The company, a clinical-stage immunology firm, focuses on developing anti-FcRn technology for autoimmune diseases. Investors can access the conference call details on Immunovant's website.
Immunovant stock hits 52-week high of $30.1 By Investing.com
Immunovant Inc.'s stock recently hit a 52-week high of $30.09, marking a 106% increase over the past year and raising its market capitalization to $6.14 billion due to strong investor confidence and pipeline developments. Despite this surge, the stock is considered overvalued by InvestingPro. However, the company recently faced a setback as its Phase 3 clinical trials for batoclimab in thyroid eye disease failed to meet the primary endpoint, leading to mixed analyst responses.
Immunovant to Report Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026, and Provide Business Update on Wednesday, May 20, 2026
Immunovant (Nasdaq: IMVT) announced it will report its financial results for the fourth quarter and fiscal year ended March 31, 2026, and provide a business update on May 20, 2026, at 8:00 a.m. ET. Investors can register online for the conference call, and webcast details will be available on the company's investor relations website. Immunovant is a clinical-stage immunology company focused on developing therapies for autoimmune diseases.
Immunovant stock hits 52-week high of $30.1
Immunovant Inc.'s stock reached a 52-week high of $30.09, reflecting a 106% increase over the past year and pushing its market capitalization to $6.14 billion. This surge is linked to positive developments in its drug pipeline, despite recent setbacks in Phase 3 trials for batoclimab which failed to meet primary endpoints. Analysts have varying outlooks, with some maintaining Outperform ratings based on the potential of a next-generation drug, while others reiterate 'Hold' ratings with lower price targets.
700,464 Shares in Immunovant, Inc. $IMVT Bought by Jennison Associates LLC
Jennison Associates LLC purchased 700,464 shares of Immunovant, Inc. (IMVT) worth approximately $17.8 million during the fourth quarter, establishing a new position. Other institutional investors like Vanguard Group Inc. and ADAR1 Capital Management LLC also increased their holdings, with institutional ownership now at 47.08%. Despite significant institutional buying, company insiders have recently sold shares primarily to cover tax withholding obligations.
Immunovant, Inc. $IMVT Shares Sold by Pictet Asset Management Holding SA
Pictet Asset Management Holding SA reduced its stake in Immunovant, Inc. ($IMVT) by 43.7% in Q4, selling 295,735 shares and retaining 380,842 shares valued at $9.68 million. Institutional investors collectively own about 47.08% of the company, while insiders have been net sellers, offloading 72,141 shares worth approximately $1.92 million. Analysts currently have a consensus "Hold" rating for Immunovant, with an average price target of $32.44, compared to its recent trading price of $27.12.
Immunovant, Inc. (NASDAQ:IMVT) Receives Average Recommendation of "Hold" from Analysts
Immunovant, Inc. (NASDAQ:IMVT) has received a consensus "Hold" recommendation from analysts, with an average one-year price target of $32.44. Recent insider selling by the CTO and CFO for tax withholding purposes has been noted, amounting to over $1.92 million in the last 90 days. The company's stock currently trades around $27.12, with a market capitalization of $5.52 billion, and recently reported quarterly EPS of -$0.61, beating estimates.
Trading Systems Reacting to (IMVT) Volatility
Quantitative Research Desk has released an analysis on Immunovant Inc. (NASDAQ: IMVT), identifying weak near-term sentiment but strong mid and long-term support signals. The report details three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—each with specific entry zones, targets, and stop losses. The analysis highlights an exceptional 42.9:1 risk-reward short setup for IMVT, targeting a 12.1% downside with minimal risk.
Immunovant | 144: Notice of proposed sale of securities pursuant to Rule 144
This document is a formal Notice of Proposed Sale of Securities pursuant to Rule 144 for Immunovant. It is a regulatory filing that indicates an intent to sell restricted or controlled securities in reliance on the Rule 144 exemption, which allows public resale without registration under certain conditions.
Immunovant director Robert Susman sells $67,979 in stock By Investing.com
Immunovant director Robert Susman sold 2,502 shares of Immunovant (NASDAQ:IMVT) common stock for a total of $67,979 on May 1, 2026, as part of a Rule 10b5-1 trading plan. Despite a 71% return over the past year, InvestingPro suggests the shares may be overvalued. This transaction follows recent news that Immunovant's Phase 3 clinical trials for batoclimab failed to meet primary endpoints, leading to mixed analyst ratings and a focus on future drug candidates.
Immunovant director Robert Susman sells $67,979 in stock By Investing.com
Immunovant director Robert Susman sold 2,502 shares of the company's common stock for a total of $67,979 on May 1, 2026. This transaction was conducted under a Rule 10b5-1 trading plan. The sale occurred despite the stock's 71% return over the past year, with InvestingPro analysis suggesting potential overvaluation.
Immunovant (IMVT) director’s 10b5-1 sale leaves 36,394 shares held
Immunovant, Inc. director Robert Graham Susman sold 2,502 shares of common stock at a weighted average price of $27.17 per share. This transaction was conducted under a Rule 10b5-1 trading plan established on December 30, 2025. Following the sale, Susman retains 36,394 shares of Immunovant common stock.
[144] Immunovant, Inc. SEC Filing
This article reports on an SEC Form 144 filing by Immunovant, Inc. (IMVT) detailing a proposed sale of 2,502 units of common stock with an aggregate market value of $67,916.79 by Morgan Stanley Smith Barney LLC. The securities were acquired on May 1, 2026, as restricted stock units from the issuer, with the sale expected to occur around the same date on NASDAQ. The filing indicates a neutral sentiment and provides current stock data and recent news for Immunovant.
Wall Street analysts predict a 55.04% upside in Immunovant (IMVT): Here's what you should know
Wall Street analysts are forecasting a significant 55.04% upside for Immunovant (IMVT) based on recent ratings and price targets. This prediction suggests strong confidence in the biotechnology company's future performance. Investors and interested parties should consider the underlying analysis when evaluating IMVT.
Immunovant (NASDAQ:IMVT) CFO Tiago Girao Sells 25,760 Shares
Immunovant CFO Tiago Girao sold 25,760 shares of the company's stock for over $763,000 to cover tax withholding obligations from vesting equity awards, reducing his ownership by 9.42%. The biopharmaceutical company, which focuses on treatments for severe autoimmune diseases, has a market cap of $5.82 billion, and analysts currently hold an average "Hold" rating with a target price of $32.44. The stock recently traded at $28.58, near its 52-week high.
Immunovant CFO Tiago Girao sells $763,011 in company stock By Investing.com
Immunovant CFO Tiago Girao sold 25,760 shares of the company's common stock for $763,011 to cover tax withholding obligations. This transaction comes as Immunovant shares are trading near their 52-week high, despite the company remaining unprofitable and recent Phase 3 clinical trials for batoclimab failing to meet primary endpoints for thyroid eye disease. Analysts have varied ratings and price targets, with some lowering targets while others maintain optimistic outlooks for different indications.
Immunovant (NASDAQ:IMVT) CTO Sells $81,573.48 in Stock
Immunovant (NASDAQ:IMVT) CTO Jay Stout sold 2,754 shares of the company stock worth $81,573.48 on April 23rd at an average price of $29.62. This transaction was to cover tax withholding obligations from vested equity awards, reducing his stake by 1.08% to 251,685 shares. The company's shares were down 1.1% to $28.58 and hold a "Hold" rating from analysts with a consensus target price of $32.44.
Immunovant (IMVT) CFO sells 25,760 shares to cover RSU tax
Immunovant, Inc.'s Chief Financial Officer, Tiago Girao, sold 25,760 shares of common stock at a weighted average price of $29.62 per share. This "sell to cover" transaction was mandated by the company to satisfy tax withholding obligations arising from the vesting of 52,097 restricted stock units (RSUs), not as a discretionary sale by the executive. After the sale, Girao directly holds 247,596 shares of Immunovant common stock.
Immunovant (IMVT) CTO sells 2,754 shares in tax sell-to-cover
Immunovant, Inc.'s Chief Technology Officer, Jay S. Stout, sold 2,754 shares of common stock at a weighted average price of $29.62 per share. This sale was a "sell to cover" transaction, mandated by the company to satisfy tax withholding obligations arising from the vesting of previously granted Restricted Stock Units (RSUs). Following the sale, Stout directly holds 251,685 shares of Immunovant common stock, indicating it was not a discretionary transaction but rather a routine tax event.
IMVT Price Today: Immunovant, Inc. Stock Price, Quote & Chart | MEXC
This article provides details on Immunovant, Inc. (IMVT) stock performance, current price, and key market data. It highlights the company's focus on developing IMVT-1402 for autoimmune diseases and offers guidance on how to buy IMVT stock on MEXC. The FAQ section addresses common investor questions regarding share price, performance trends, valuation, and financial reporting.
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock new upside?
Immunovant Inc, a clinical-stage biotech company focused on autoimmune diseases, is gaining attention for its lead candidate, batolimab, and its subcutaneous version, IMVT-1402. These FcRn inhibitors target conditions like thyroid eye disease (TED) and myasthenia gravis (MG), addressing significant unmet medical needs. Analysts are largely positive, citing the validated FcRn mechanism and potential blockbuster sales, though trial success and competition remain key risks for investors.
Immunovant Inc stock (US45258Q1058): Is its autoimmune pipeline strong enough to unlock biotech upside?
Immunovant Inc. (IMVT) is a clinical-stage immunology company developing innovative antibody therapies for autoimmune diseases, primarily focusing on batoclimab and imsidolimab for conditions like thyroid eye disease and myasthenia gravis. The company operates with an asset-light model, leveraging partnerships and focusing on high-potential targets like the FcRn pathway. While analysts are cautiously optimistic, citing pipeline depth and potential catalysts like Phase 3 data, the company faces typical biotech risks including clinical failure, dilution, and intense competition.
Immunovant (NASDAQ:IMVT) Reaches New 12-Month High - Should You Buy?
Immunovant (NASDAQ:IMVT) recently hit a new 52-week high of $29.34, with its stock up 7.1% on Friday. Despite an average "Hold" rating from analysts and an average price target of $32.44, some analysts like Guggenheim and Wolfe Research have raised their targets with "Buy" and "Outperform" ratings, respectively, while Weiss issued a "Sell." The company beat its EPS consensus last quarter, but is still projected to have negative FY EPS, and insiders have recently sold shares primarily for tax withholding purposes.
Immunovant stock hits 52-week high at 29.26 USD By Investing.com
Immunovant Inc. (IMVT) stock reached a 52-week high of $29.27, reflecting strong investor confidence despite recent setbacks in its Phase 3 clinical trials for batoclimab. While the stock has shown significant returns over the past year, InvestingPro's Fair Value analysis suggests it may be overvalued. Analysts have mixed ratings, maintaining price targets between $23.00 and $54.00, considering the potential of its next-generation FcRn IMVT-1402 in Graves’ disease.
Immunovant falls on late-stage trial setback for TED therapy
Immunovant's stock fell due to a setback in a late-stage trial for its Thyroid Eye Disease (TED) therapy. This negative development suggests challenges for the company's drug development pipeline in a key therapeutic area.
IMVT Maintained by Goldman Sachs -- Price Target Raised to $32
Goldman Sachs has maintained a Neutral rating for Immunovant (IMVT) but raised its price target from $29 to $32, indicating a cautiously positive outlook for the company's valuation. While Immunovant, a clinical-stage immunology company, shows strong financial strength with a GF Score™ of 37, it faces challenges in profitability and has experienced significant insider selling. Investors are advised to exercise caution and conduct further examination due to the low profitability rank and lack of insider purchases.
JPMorgan Chase & Co. Sells 402,933 Shares of Immunovant, Inc. $IMVT
JPMorgan Chase & Co. significantly reduced its stake in Immunovant, Inc. (NASDAQ:IMVT) by selling 402,933 shares, an 84.2% decrease, leaving it with 75,330 shares valued at $1.214 million as of the third quarter. Insiders also sold 19,083 shares in the last quarter. Despite mixed analyst ratings, the company currently holds a "Hold" consensus with a target price of $32.00, trading near $25.65 with a market capitalization of $5.22 billion.
Jay Stout Sells 10,132 Shares of Immunovant (NASDAQ:IMVT) Stock
Jay Stout, CTO of Immunovant (NASDAQ:IMVT), sold 10,132 shares of the company's stock on April 8th for $24.83 per share to cover tax withholding obligations associated with vested equity. This transaction reduced his direct stake by 3.83% to 254,439 shares. Following the news, Immunovant's stock traded down by approximately 4.5% to $24.50, despite the company reporting better-than-expected earnings.
LifeSci Capital Maintains Immunovant(IMVT.US) With Buy Rating, Maintains Target Price $42
LifeSci Capital has reiterated its Buy rating for Immunovant (IMVT.US) and maintained its price target at $42. This indicates continued confidence in the company's stock from the investment firm.
Van Tuyl, Immunovant’s chief legal officer, sells $128k in IMVT stock
Immunovant's chief legal officer, Christopher Van Tuyl, sold 5,165 shares of IMVT stock worth $128,246 to cover tax obligations from vested restricted stock units. This sale occurred despite the stock's strong performance over the past year. The article also notes recent analyst activities and clinical trial results for Immunovant.
[Form 4] Immunovant, Inc. Insider Trading Activity
Immunovant, Inc.'s Chief Operating Officer, Gloria Melanie, reported an open-market sale of 8,722 shares of common stock at a weighted average price of $24.83 per share. This "sell to cover" transaction was conducted to satisfy tax withholding obligations related to the vesting of 19,045 restricted stock units (RSUs) on April 1, 2026. Following this sale, Melanie Gloria directly holds 245,222 shares of Immunovant common stock.
Immunovant (NASDAQ: IMVT) CTO sells 10,132 shares for RSU tax obligations
Immunovant's Chief Technology Officer, Jay S. Stout, sold 10,132 shares of common stock on April 8, 2026, at a weighted average price of $24.83 per share. These sales were mandatory "sell to cover" transactions to meet tax withholding obligations from vested restricted stock units granted in 2024 and 2025, not discretionary decisions. Following these transactions, Stout still holds 254,439 shares of Immunovant common stock.
Immunovant (IMVT) CLO sells 5,165 shares to cover RSU tax bill
Immunovant's Chief Legal Officer, Christopher Van Tuyl, sold 5,165 shares of common stock on April 8, 2026, at an average price of $24.83 per share. This sale was a non-discretionary transaction, mandated by the company, to cover tax withholding obligations tied to the vesting of previously granted restricted stock units. Following this transaction, Van Tuyl directly holds 183,231 shares of Immunovant common stock.
(IMVT) and the Role of Price-Sensitive Allocations
The article provides a quantitative analysis of Immunovant Inc. (IMVT), indicating a neutral near and mid-term outlook but a strong long-term positive bias. It highlights an exceptional 48.0:1 risk-reward setup and outlines three AI-generated institutional trading strategies based on different risk profiles and holding periods, including position trading, momentum breakout, and risk hedging. The analysis emphasizes the role of price-sensitive allocations in its predictive AI models.
